Lv7
4910 积分 2022-08-11 加入
OA04.04 Sacituzumab Govitecan as Second-Line Treatment in Patients with Extensive Stage Small Cell Lung Cancer
17天前
已关闭
Preclinical Evaluation of JAB-2485, a Potent AURKA Inhibitor with High Selectivity and Favorable Pharmacokinetic Properties
2个月前
已完结
Cisplatin Mouse Models: Treatment, Toxicity and Translatability
2个月前
已完结
Turn on, tune in, turnover! Target biology impacts in vivo potency, efficacy, and clearance
3个月前
已完结
Pharmacokinetics and Pharmacodynamics of TAK-164 Antibody Drug Conjugate Coadministered with Unconjugated Antibody
3个月前
已完结
Advancing preclinical cancer models to assess clinically relevant outcomes
5个月前
已完结
Evaluation of Tumor Growth Inhibition in Preclinical Tumor Models: A Quantitative Approach
6个月前
已完结
Spotlight on Ideal Target Antigens and Resistance in Antibody-Drug Conjugates: Strategies for Competitive Advancement
6个月前
已完结
SHR-A1811, a novel anti-HER2 antibody–drug conjugate with optimal drug-to-antibody ratio, superior bystander killing effect and favorable safety profiles
8个月前
已关闭
Humanized mouse models for immuno-oncology research
9个月前
已完结
皖公网安备34019202002308
